肝脾舒合剂治疗肝热脾虚型便秘型肠易激综合征临床观察

目的:观察肝脾舒合剂治疗肝热脾虚型便秘型肠易激综合征(C-IBS)的临床疗效。方法:将60例肝热脾虚型C-IBS患者分两组,治疗组40例予GPS合剂治疗,对照组20例予莫沙必利治疗,疗程8周。观察两组临床疗效、主要症状评分和生活质量评分变化。结果:治疗组总有效率为90.00%,对照组为60.00%,两组比较差异有显著性意义(P<0.05);治疗后两组主要症状积分均有降低(P<0.05),且治疗组低于对照组(P<0.05);两组患者生活质量均有不同程度改善(P<0.05),且治疗组改善优于对照组(P<0.05)。结论:肝脾舒合剂能改善肝热脾虚型C-IBS患者临床症状,提高其生活质量。

Clinical Observation of "Ganpishu Mixture" in Treating Constipation-predominant Irritable Bowel Syndrome of Liver Heat and Spleen Deficiency

Objective: To observe the clinical efficacy of "Ganpishu Mixture" in the treatment of constipation-predominant irritable bowel syndrome(C-IBS) of liver heat and spleen deficiency.Methods: Sixty subjects were randomized into two groups: treatment group in which 40 cases were treated with "Ganpishu Mixture" and control group in which 20 cases were treated with mosapride citrate tablets,with a course of 8 weeks.The clinical efficacy,the main symptom scores and quality of life scores were observed.Results: The total effective rate was 90.00% in the treatment group and 60.00% in the control group,with a striking difference between the two groups(P<0.05).After treatment,the main symptom scores were decreased in both groups(P<0.05),with more significant decrease in the treatment group than in the control group(P<0.05);the quality of life was improved in both groups(P<0.05),with more significant improvement in the treatment group than in the control group(P<0.05).Conclusion: "Ganpishu Mixture" can improve the clinical symptoms and enhance the life of quality in the treatment of C-IBS of liver heat and spleen deficiency.